It seems you're asking about a compound with a very specific chemical name: **1,3-dichloro-6-trifluoromethyl-9-phenanthryl-3-(n-butyl)aminopropanol**.
This compound is likely **not a well-known or widely researched molecule**.
Here's why:
* **The structure is complex:** The name indicates a complex organic molecule with multiple functional groups.
* **No known uses:** There are no readily available scientific publications or databases that mention this exact compound and its applications.
* **Possible synthetic target:** It's possible that this compound could be a target for synthesis in research, but it wouldn't be a commonly studied compound.
**Here's what we can glean from the name itself:**
* **1,3-dichloro-6-trifluoromethyl-9-phenanthryl:** This part refers to the core structure of the molecule, likely a substituted phenanthrene. Phenanthrenes are polycyclic aromatic hydrocarbons (PAHs) with interesting properties.
* **3-(n-butyl)aminopropanol:** This part indicates a side chain with a butyl group attached to an amino group, which in turn is attached to a propanol molecule.
**To gain more information, you would need to:**
* **Consult specialized databases:** Search for the compound in databases like PubChem or Reaxys.
* **Contact researchers:** Reach out to experts in organic synthesis or medicinal chemistry who might have knowledge of similar molecules.
* **Investigate the context:** Determine where you encountered this name (e.g., a research paper, a patent, etc.) to understand its potential significance.
It's highly probable that this compound is not a commonly known or widely researched one. To learn more about its potential importance, you'll need to conduct further investigation as outlined above.
1,3-dichloro-6-trifluoromethyl-9-phenanthryl-3-(n-butyl)aminopropanol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 115076 |
| CHEMBL ID | 3229137 |
| MeSH ID | M0131000 |
| Synonym |
|---|
| 69756-48-5 |
| 3-(butylamino)-1-[1,3-dichloro-6-(trifluoromethyl)-9-phenanthryl]propan-1-ol |
| 1,3-dichloro-6-trifluoromethyl-9-[1-hydroxy-3-(n-n-butylamino)propyl]phenanthrene |
| alpha-(2-(butylamino)ethyl)-1,3-dichloro-6-(trifluoromethyl)-9-phenanthrenemethanol |
| desbutylhalofantrine |
| 9-phenanthrenemethanol, alpha-(2-(butylamino)ethyl)-1,3-dichloro-6-(trifluoromethyl)- |
| monodesbutylhalofantrine |
| 1,3-dichloro-6-trifluoromethyl-9-phenanthryl-3-(n-butyl)aminopropanol |
| dctfmp |
| 3-(butylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol |
| 7k35ddv85x , |
| unii-7k35ddv85x |
| osu-255 |
| 9-phenanthrenemethanol, .alpha.-(2-(butylamino)ethyl)-1,3-dichloro-6-(trifluoromethyl)- |
| n-desbutylhalofantrine |
| CHEMBL3229137 |
| n-debutylhalofantrine |
| DTXSID40989921 |
| Q27268443 |
| fyhchsnoxwvjjt-uhfffaoysa-n |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Although it is difficult to ascertain causality and to estimate overall incidence, a significant number of adverse events related to the cardiovascular system were reported, including QT interval prolongation, life-threatening arrhythmias, and sudden death." | ( Mechanism of cardiotoxicity of halofantrine. Schuster, BG; Wang, WX; Wesche, DL; Woosley, RL, 2000) | 0.31 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " It was concluded that DHF possesses a pharmacokinetic profile similar to that of HF, each possessing low values of clearance and high volume of distribution." | ( Stereoselective pharmacokinetics of desbutylhalofantrine, a metabolite of halofantrine, in the rat after administration of the racemic metabolite or parent drug. Brocks, DR, 2000) | 0.31 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " We suggest that the large intersubject variability in plasma drug concentrations may relate in part to its poor and inconsistent bioavailability and this rather than true resistance might be responsible for some of the treatment failures." | ( Pharmacokinetics of halofantrine in Thai patients with acute uncomplicated falciparum malaria. Bunnag, D; Edwards, G; Karbwang, J; Milton, KA; Na Bangchang, K; Ward, SA, 1991) | 0.28 |
| " Oral bioavailability estimates of DHF enantiomers (>59%) were higher than those previously estimated for HF in the rat." | ( Stereoselective pharmacokinetics of desbutylhalofantrine, a metabolite of halofantrine, in the rat after administration of the racemic metabolite or parent drug. Brocks, DR, 2000) | 0.31 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Halofantrine was administered on two separate days at a total oral dosage of 24 mg/kg/day in three doses over a 12-hr period." | ( Electrocardiographic changes and halofantrine plasma level during acute falciparum malaria. Bernard, J; Chaudet, H; Doury, JC; Imbert, P; Keundjian, A; Touze, JE; Viguier, A, 1996) | 0.29 |
| " Plasma, adipose, and highly perfused tissues heart, lung, liver, kidney, spleen and brain were harvested for up to 48 h after dosing animals with 2 mg/kg (+/-)-HF intravenously by tail vein." | ( The effect of experimental hyperlipidemia on the stereoselective tissue distribution, lipoprotein association and microsomal metabolism of (+/-)-halofantrine. Brocks, DR; Fleischer, JG; Patel, JP; Wasan, KM, 2009) | 0.35 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1123507 | Antimalarial activity against Plasmodium berghei | 1979 | Journal of medicinal chemistry, Apr, Volume: 22, Issue:4 | Quantitative structure-activity relationships in 1-aryl-2-(alkylamino)ethanol antimalarials. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (9.09) | 18.7374 |
| 1990's | 20 (60.61) | 18.2507 |
| 2000's | 10 (30.30) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.40) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (11.11%) | 5.53% |
| Reviews | 1 (2.78%) | 6.00% |
| Case Studies | 1 (2.78%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 30 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||